Pfizer and Eisai Commence Co-promotion of “NURTEC(R)” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
TOKYO, July 27, 2026 – (JCN Newswire via SeaPRwire.com) – Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi,“Pfizer”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the companies will commence the co-promotion
More